Radiation-induced mucositis of the aerodigestive tract: Prevention and treatment. MASCC/ISOO mucositis group's recommendations;Mucite radio-induite des voies aérodigestives: Prévention et prise en charge. Recommandations du groupe mucites MASCC/ISOO

Bulletin du Cancer

Volumn 93, Issue 2, 2006, Pages 201-211

  Bensadoun, René Jean ^a   Le Page, Fabien ^a   Darcourt, Vincent ^a   Bensadoun, Francis ^a   Ciais, Gaston ^a   Rostom, Yousri A ^b   Poissonnet, Gilles ^a   Dassonville, Olivier ^a   Demard, François ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b Radiotherapy Center   (Egypt)

Author keywords

3D conformal radiotherapy; Low level laser therapy (LLLT); Prevention; Radiation induced acute mucositis; Treatment

Indexed keywords

AMIFOSTINE; BENZYDAMINE; CHLORHEXIDINE; PALIFERMIN; PENTOXIFYLLINE; SALAZOSULFAPYRIDINE; SUCRALFATE;

ACUTE TOXICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DIGESTIVE SYSTEM; DISEASE CONTROL; DRUG EFFECT; GASTROINTESTINAL MUCOSA; HEAD AND NECK CANCER; HUMAN; LOW LEVEL LASER THERAPY; MUCOSA INFLAMMATION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RESPIRATORY SYSTEM; SCAR FORMATION; SURGICAL TECHNIQUE;

DIGESTIVE SYSTEM DISEASES; HUMANS; MUCOSITIS; RADIATION INJURIES; RESPIRATORY TRACT DISEASES;

EID: 33645231484     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Maciejewski B, Skladowski K, Pilecki B, Taylor JM, Withers RH, Miszczyk L, et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiother Oncol 1996; 40: 137-45.
2. Bensadoun RJ, Etienne MC, Dassonville O, Chauvel P, Pivot X, Marcy PY, et al. Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multi-center phase II study. Int J Radiat Oncol Biol Phys 1998; 42: 237-45.
3. Bourhis J, Fortin A, Dupuis O, Domenge C, Lusinchi A, Marandas P, et al. Very accelerated radiation therapy: preliminary results in locally unresectable head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995; 32: 747-52.
4. Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 1995; 31: 1141-64.
5. Fu KK, Pajak TF, Marcial VA, Ortiz HG, Rotman M, Asbell SO, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 1995; 32: 577-88.
6. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A radiation therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
7. Horiot JC, Le Fur R, NGuyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25: 231-41.
8. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44: 111-21.
9. Kaanders JH, van Daal WA, Hoogenraad WJ, van der Kogel AJ. Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity. Int J Radiat Oncol Biol Phys 1992; 24: 497-503.
10. Lusinchi A, Lartigau E, Luboinski B, Eschwège F. Accelerated radiation therapy in the treatment of very advanced and inoperable head and neck cancers. Int J Radiat Oncol Biol Phys 1994; 29: 149-52.
11. Nguyen TD, Panis X, Froissart D, Legros M, Coninx P, Loirette M. Analysis of late complications after rapid hyperfractionated radiotherapy in advanced head and neck cancers. Int J Radiat Oncol Biol Phys 1988; 14: 23-5.
12. Nyman J, Turesson I. Does the interval between fractions matter in the range of 4-8 h in radiotherapy? A study of acute and late human skin reactions. Radiother Oncol 1995; 34: 171-8.
13. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: the university of Florida experience. Head Neck 1993; 15: 87-96.
14. Adelstein DJ, Kalish LA, Adams GL, Wagner H, Oken MM, Remick SC, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group Pilot Study. J Clin Oncol 1993; 11: 2136-42.
15. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-804.
16. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-6.
17. Forastiere AA, Trotti A. Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 1999; 91: 2065-6.
18. Merlano M, Corvo R, Margarino G, Benasso M, Rosso R, Sertoli MR, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 1991; 67: 915-21.
19. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949-55.
20. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100: 2026-46.
21. Sixou JL, Medeiros-Batista A, Bonnaure-Mallet M. Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy. Oral Oncol 1996; 32: 306-10.
22. Sonis ST. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomato-toxicity. Oral Oncol 1998; 34: 39-43.
23. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multi-center phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999; 7: 244-52.
24. Kaanders JH, van der Kogel AJ, Ang KK. Altered fractionation: limited by mucosal reactions? Radiother Oncol 1998; 50: 247-60.
25. Macmillan CH, Carrick K, Bradiey J, Morgan DL. Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck. Br J Radiol 1991; 64: 941-6.
26. Chambers MS, Toth BB, Martin JW, Fleming TJ, Lemon JC. Oral and dental management of the cancer patient: prevention and treatment of complications. Support Care Cancer 1995; 3: 168-75.
27. Peters LJ, Ang KK, Thanies HD. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Ann Oncol 1988; 27: 185-94.
28. Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Oral Oncol 1994; 30: 93-7.
29. Raber Durlacher JE, Abraham L, van Leevwen EF, Lustig KH, van Winkelhof AJ. The prevention of oral complications in bone marrow transplantations by means of oral hygiene and dental intervention. Neth J Med 1989; 34: 98-108.
30. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000; 47: 1-12.
31. Sonis ST, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991; 12: 92-5.
32. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025.
33. Sonis ST. Validation of a new scoring system for assessment of clinical trials research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 1999; 85: 2103-13.
34. Bensadoun RJ, Magné N, Marcy PY, Demard F. Chemotherapy and radiotherapy induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 2001; 258: 481-7.
35. Cox JD, Steiy J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6.
36. Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncol 1998; 34: 63-71.
37. Spijkervet FK, van Saene HK, Panders AK, Vermey A, Mehta DM. Scoring irradiation mucositis in head and neck cancer patients. J Oral Pathol 1989; 18: 167-71.
38. Tardieu C, Cowen D, Thirion X, Franquin JC. Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Eur J Cancer 1996; 32: 381-7.
39. Somerfield M, Padberg J, Pfister D, et al. ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers Current Comments 2000; 1: 861-6.
40. Mose S, Adamietz IA, Saran F, Thilmann C, Heyd R, Knecht R, et al. Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis. Am J Clin Oncol 1997; 20: 407-11.
41. Magné N, Marcy PY, Chamorey E, Guardiola E, Pivot X, Schneider M, et al. Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: a long-term quality of life analysis. Head Neck 2001; 23: 678-82.
42. Magné N, Marcy PY, Foa C, Falewee MN, Schneider M, Demard F, et al. Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients. Eur Arch Otorhinolaryngol 2001; 258: 89-92.
43. Marcy PY, Magné N, Bensadoun RJ, Bleuse A, Falewee MN, Viot M, et al. Systematic percutaneous fluoroscopic gastrostomy for concomitant radiochemotherapy of advanced head and neck cancer: optimization of therapy. Support Care Cancer 2000; 8: 410-3.
44. Marcy PY, Magné N, Bensadoun RJ, Bentolila F, Bleuse A, Dassonville O, et al. Percutaneous endoscopic gastrostomy: cost/benefit analysis in patients with carcinoma of the upper aerodigestive tract. Bull Cancer 2000; 87: 329-33.
45. Symonds RP, Mcih-oy P, Khon-ami J, Paul J, Pyper E, Alcock SR, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 1996; 74: 312-7.
46. Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, Macphail L, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23: 921-7.
47. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45.
48. Wagner W, Prott FJ, Schönekas KG. Amifostine: a radioprotector in locally advanced head and neck tumors. Oncol Rep 1998; 5: 1255-7.
49. Barasch A, Peterson D, Tanzer JM, D'ambrosio JA, Nuki K, Schubert M, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995; 76: 2550-6.
50. Ciais G, Namer M, Schneider M, Demard F, Pourreau-Schneider N, Martin PM, et al. La laserthérapie dans la prévention et le traitement des mucites liées à la chimiothérapie anticancéreuse. Bull Cancer 1992; 79: 183-91.
51. Schubert MM, Franquin JC, Niccoli-Filho F, Marcial F, Lloid M, Kelly J. Effects of low-energy laser on oral mucositis: a phase I/II pilot study. Cancer Res Wkly 1994; 7: 14.
52. Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C, et al. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 38: 697-703.
53. Meredith R, Salter M, Kim R, Spencer S, Weppelman B, Rodu B, et al. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 13: 275-9.
54. Labar B, Mrsic M, Pavietic Z, Bogdanic V, Nemet D, Aurer I, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11: 379-82.
55. Cariee L, Petros WP, Rosner GL, Gilben C, Moore S, Affronti ML, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose ranging study. Cytokine 1995; 7: 471-7.
56. Gordon B, Spadineer A, Hodges E, Ruby E, Stanley R, Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 1994; 12: 1917-22.
57. Kannan V, Bapsy PP, Anantha N, Doval DC, Vaithianathan H, Banumathy G, et al. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys 1997; 37: 1005-10.
58. Sonis ST, Van Vugt AG, Brien JP, Muska AD, Bruskin AM, Rose A, et al. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997; 33: 47-54.